2026-01-23
In an exciting development, the research team from the Oncology Center at Foshan Chancheng Hospital has received a significant honor. Their groundbreaking work on Stereotactic Central Ablative Radiotherapy (SCART) technology has been selected for a Featured Presentation at the upcoming Radiosurgery Society (RSS) Annual Meeting in 2026. The presentation will be part of the esteemed "Spatially Fractionated Radiotherapy (SFRT)" session.
SCART technology represents a leading-edge approach in precision radiotherapy, specifically designed to address a classic clinical challenge: large, recurrent, and often treatment-resistant tumors. This breakthrough has already shown promising clinical results, improving quality of life and extending survival for nearly 500 patients to date.
The RSS Annual Meeting is a premier global forum in North American radiosurgery, renowned for its rigorous peer-review process and high academic standards. With a consistently low acceptance rate, being selected for a featured main-session presentation is a rare distinction. For a Chinese medical research team, this recognition signifies that their work's direction and outcomes are widely acknowledged by leading international experts as potentially transformative.
In addition to the featured presentation by Dr. Yang Jun, three other collaborative studies led by his clinical and scientific team—including Director Yuan Jie, Dr. Li Yuan, and Medical Physicist Song Junqi from Foshan Chancheng Hospital, alongside collaborators from the University of Kentucky Department of Radiation Oncology and Professor Weisi Yan, VP of Research at Junxin Med—have been selected for oral presentations across various sub-sessions. A further study on medical physics has been accepted for poster presentation.
This collective achievement highlights the team's comprehensive research strategy around the SCART framework, which operates simultaneously across three critical dimensions: clinical efficacy exploration, physics plan innovation, and biological mechanism investigation. The fact that a single team has been invited to present on multiple core aspects of the technology at a conference of RSS's caliber is noteworthy. It underscores not only the emergence of a clear and robust solution—conceived through Sino-American collaboration—to the complex problem of treating large tumors but also reflects the intense international interest in such high-precision technological advancements.
The recognized research directions perfectly map the team's scientific pathway: clinical studies report application data and safety; physics research delves into the precise realization of dose sculpting; and biological studies seek to uncover the underlying mechanisms of action. This virtuous cycle—where clinical practice drives fundamental physics and biological research, which in turn refines the clinical pathway—exemplifies a robust scientific logic for tackling intricate clinical problems.
Gaining a multi-faceted voice on the international stage, which demands "hardcore" scientific evidence, speaks volumes. It suggests that the complex clinical problem of massive tumors and the SCART therapeutic framework proposed by the Junxin research team are now integral to the main narrative of global radiosurgery advancement.
To stand among the world's brightest minds at the most authoritative academic forums, addressing the most difficult questions about life, is the shared pursuit of every team dedicated to oncology. The path is long, but each rigorous exchange and validation represents a solid step forward.
In our next feature, we will invite several researchers to explain, in accessible terms, the purpose and significance of their SCART-related studies.
